The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | First-in-Human study of TTI-621 in R/R hematologic malignancies
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, gives updates on the first-in-human phase I study of TTI-621 in patients with relapsed/refractory hematologic malignancies. TTI-621 (SIRPαFc) is a novel biologic that targets CD47 and shows promising anti-tumor activity. Dosing was initially difficult to ascertain as platelets also contain these signals and were depleted as a result. However, dosing has since been clarified and the results presented at ASH 2020. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding: Bristol Myers Squibb, Seattle Genetics, ADC Therapeutics, Affimed, Trillium, AI Therapeutics, Regeneron
